LC
BIIB icon

Landaas & Company’s Biogen BIIB Stock Holding History

Landaas & Company’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-312
Closed -$91K – 88
2018
Q2 		$91K Buy
+312
New +$87.7K 0.07% 102
2018
Q1 		– Sell
-312
Closed -$99K – 82
2017
Q4 		$99K Hold
312
– – 0.09% 94
2017
Q3 		$98K Buy
+312
New +$92.4K 0.09% 95

Other funds holding BIIB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Landaas & Company's BIIB Position: Q3 2018 in Review

Landaas & Company sold out of Biogen (BIIB) in Q3 2018, closing a stake of 312 shares — an estimated $91K sold.

Landaas & Company first reported a position in BIIB in Q3 2017 and held it in 3 quarters. The position peaked at $99K in Q4 2017. 1,146 funds tracked by Wall St. Rank hold BIIB as of Q3 2018.

  • Landaas & Company reported no remaining Biogen position as of Q3 2018 after selling out during the quarter.
  • Landaas & Company sold 312 Biogen shares in Q3 2018, an estimated $91K.
  • Landaas & Company first reported a position in Biogen in Q3 2017 and held it in 3 quarters.
  • Landaas & Company's Biogen position peaked at $99K in Q4 2017.
  • 1,146 funds tracked by Wall St. Rank held Biogen as of Q3 2018.

Based on Landaas & Company's 13F filing for Q3 2018, filed 14 Nov 2018.